Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 10/20 | 0.46 |
| ▸ | GRM5 | P41594 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7344367 | 0.84 | PLAU (0.48) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7359141 | 0.83 | PLAU (0.50) | — | |
| SCHEMBL7853605 | 0.80 | PLAU (0.48) | NPC1RAB9A | |
| SCHEMBL7853919 | 0.79 | PLAU (0.66) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7854754 | 0.79 | PLAU (0.64) | — | |
| Trifluoroacetic Acid SCHEMBL7852367 | 0.78 | GRM5 (0.54) | SORT1GRM5NPC1RAB9A | |
| SCHEMBL7340320 | 0.77 | GRM5 (0.63) | GRM5NPC1RAB9A | |
| SCHEMBL7856137 | 0.75 | PLAU (0.67) | — | |
| SCHEMBL7854268 | 0.75 | NPC1 (0.46) | NPC1MAPTRAB9A | |
| SCHEMBL7855528 | 0.74 | PLAU (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | SORT1 1970/4885GRM5 4207/4885NPC1 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.